Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cetrimonium→

Cetrimonium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
6899-10-1
Molecular formula
C19H42N+
Molecular weight
284.5 g/mol
Drug class
Quaternary ammonium cationic surfactantantimicrobial preservative and excipient
Mechanism of action
Interacts with negatively charged cell membranes and disrupts membrane integrity. In pharmaceutical and cosmetic formulations, cetrimonium compounds may act as preservatives, emulsifiers or conditioning agents.
Indications / reported uses
  • Use as a formulation preservative, surfactant or conditioner in topical, cosmetic and pharmaceutical preparations; a general systemic therapeutic indication should not be assigned to the cationic surfactant alone

Sources: PubChem — Cetrimonium · European Commission CosIng — Cetrimonium compounds · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Quaternary ammonium cationic surfactant; antimicrobial preservative and excipient

Mechanism of action

Interacts with negatively charged cell membranes and disrupts membrane integrity. In pharmaceutical and cosmetic formulations, cetrimonium compounds may act as preservatives, emulsifiers or conditioning agents.

General use cases

  • Use as a formulation preservative, surfactant or conditioner in topical, cosmetic and pharmaceutical preparations; a general systemic therapeutic indication should not be assigned to the cationic surfactant alone

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Cetrimonium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cetrimonium Permitted Daily Exposure (PDE) report (the Cetrimonium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cetrimonium Occupational Exposure Limit (OEL) report (the Cetrimonium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.